CERo Therapeutics Soars 89.72% on FDA Orphan Designation

On June 17, 2025, CERo Therapeutics surged 89.72% in pre-market trading, marking a significant rise in its stock price.

The Food and Drug Administration has granted orphan designation to a drug under development by CeroTherapeutics aimed at treating acute myeloid leukemia. This designation is a significant step for the company as it seeks to advance its treatment options for this challenging blood cancer.

Wall Street analysts have set an average price target of $60.00 for CERo Therapeutics, with a high estimate of $60.00 and a low estimate of $60.00. This target implies an upside of 773.62% from the current price. The consensus recommendation from brokerage firms indicates an "Outperform" status for the company, with an average rating of 2.5 on a scale where 1 signifies Strong Buy and 5 denotes Sell.